GlycoMimetics (GLYC) to Present Further Analysis of Data From Phase 1/2 AML Trial of Uproleselan at ASH

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. IBM
10. HOOD

Go back to GlycoMimetics (GLYC) to Present Further Analysis of Data From Phase 1/2 AML Trial of Uproleselan at ASH

GlycoMimetics (GLYC) Tops Q2 EPS by 8c

November 7, 2019 8:26 AM EST

GlycoMimetics (NASDAQ: GLYC) reported Q2 EPS of ($0.31), $0.08 better than the analyst estimate of ($0.39).

In the third quarter of 2019, we continued to progress the late-stage clinical development of our wholly-owned product candidate, uproleselan. Our Company-sponsored Phase 3 trial in relapsed or refractory AML patients and the NCI-sponsored Phase 3 trial for newly diagnosed patients with AML both advanced during the quarter. We are also working with the Duke Cancer Institute towards... More